AR109386A1 - Formulación farmacéutica estable que comprende una composición de un agente tensioactivo pulmonar reconstituido - Google Patents
Formulación farmacéutica estable que comprende una composición de un agente tensioactivo pulmonar reconstituidoInfo
- Publication number
- AR109386A1 AR109386A1 ARP170102320A ARP170102320A AR109386A1 AR 109386 A1 AR109386 A1 AR 109386A1 AR P170102320 A ARP170102320 A AR P170102320A AR P170102320 A ARP170102320 A AR P170102320A AR 109386 A1 AR109386 A1 AR 109386A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical formulation
- composition
- stable pharmaceutical
- reconstituted pulmonary
- reconstituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0082—Lung surfactant, artificial mucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Formulación farmacéutica física y químicamente estable en forma de suspensión acuosa, que comprende un agente tensioactivo pulmonar reconstituido. Esta formulación es apropiada para prevenir y/o tratar el síndrome de dificultad respiratoria (RDS) u otros trastornos respiratorios. Reivindicación 12: Un método para evitar el incremento de la viscosidad durante el almacenamiento de una formulación farmacéutica que es una suspensión acuosa de una composición de un agente tensioactivo pulmonar reconstituido que comprende fosfolípidos en combinación con análogos sintéticos de proteínas SP-C y SP-B, caracterizado porque comprende ajustar el pH entre 6,4 y 7,6 con un agente amortiguador apropiado.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16185516 | 2016-08-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR109386A1 true AR109386A1 (es) | 2018-11-28 |
Family
ID=56800200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170102320A AR109386A1 (es) | 2016-08-24 | 2017-08-22 | Formulación farmacéutica estable que comprende una composición de un agente tensioactivo pulmonar reconstituido |
Country Status (12)
Country | Link |
---|---|
US (1) | US10543256B2 (es) |
EP (1) | EP3503905A1 (es) |
KR (1) | KR102395835B1 (es) |
CN (1) | CN109562139A (es) |
AR (1) | AR109386A1 (es) |
BR (1) | BR112019003673A2 (es) |
CA (1) | CA3029456A1 (es) |
MA (1) | MA46034A (es) |
MX (1) | MX2019001854A (es) |
RU (1) | RU2748417C2 (es) |
TW (1) | TW201811311A (es) |
WO (1) | WO2018036819A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114159546B (zh) * | 2021-12-20 | 2024-06-04 | 北京双鹤润创科技有限公司 | 新一代合成肺表面活性物质制剂及其临床应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5260273A (en) | 1988-01-06 | 1993-11-09 | The Scripps Research Institute | Pulmonary surfactant protein and related polypeptide |
CA2063273C (en) * | 1989-07-11 | 2002-09-24 | Bradley J. Benson | Surfactant compositions and methods |
EP0976403A1 (en) * | 1998-07-30 | 2000-02-02 | Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) | Adjuvant comprising pulmonary surfactant |
EP1189625A1 (en) | 1999-06-11 | 2002-03-27 | Byk Gulden Lomberg Chemische Fabrik GmbH | Pharmaceutical preparation containing modifications of surfactant protein b (sp-b) and surfactant protein c (sp-c) |
JP2003510263A (ja) * | 1999-09-24 | 2003-03-18 | アルコン,インコーポレイテッド | シプロフロキサシンおよびデキサメタゾンを含有する局所用懸濁処方物 |
US20050031706A1 (en) * | 2003-08-06 | 2005-02-10 | Pena Lorraine E. | Viscosity-stable compositions useful for treating gastrointestinal disorders |
CA2658478C (en) | 2006-07-20 | 2018-02-13 | University Of Rochester | Synthetic lung surfactant and use thereof |
DK2078038T3 (da) | 2006-10-13 | 2013-12-02 | Chiesi Farma Spa | Rekonstituerede surfaktanter med forbedrede egenskaber |
US8399406B2 (en) * | 2009-06-05 | 2013-03-19 | Chiesi Farmaceutici S.P.A. | Reconstituted surfactant composition containing analogs of surfactant protein B (SP-B) and surfactant protein C (SP-C) |
CN102049040A (zh) * | 2009-10-30 | 2011-05-11 | 北京隆旗生物科技有限公司 | 人工表面活性物质混合液及其制备与应用 |
CN104812771B (zh) * | 2012-11-21 | 2018-03-30 | 奇斯药制品公司 | 重建的肺表面活性剂 |
US10738079B2 (en) * | 2017-04-14 | 2020-08-11 | Emory University | Compositions and methods for managing respiratory conditions |
-
2017
- 2017-08-09 EP EP17755111.6A patent/EP3503905A1/en active Pending
- 2017-08-09 CN CN201780047045.6A patent/CN109562139A/zh active Pending
- 2017-08-09 MX MX2019001854A patent/MX2019001854A/es unknown
- 2017-08-09 BR BR112019003673-3A patent/BR112019003673A2/pt unknown
- 2017-08-09 RU RU2019107379A patent/RU2748417C2/ru active
- 2017-08-09 WO PCT/EP2017/070169 patent/WO2018036819A1/en unknown
- 2017-08-09 MA MA046034A patent/MA46034A/fr unknown
- 2017-08-09 CA CA3029456A patent/CA3029456A1/en active Pending
- 2017-08-09 KR KR1020197002663A patent/KR102395835B1/ko active IP Right Grant
- 2017-08-21 TW TW106128278A patent/TW201811311A/zh unknown
- 2017-08-22 AR ARP170102320A patent/AR109386A1/es unknown
- 2017-08-23 US US15/683,822 patent/US10543256B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
RU2748417C2 (ru) | 2021-05-25 |
CN109562139A (zh) | 2019-04-02 |
RU2019107379A (ru) | 2020-09-25 |
MA46034A (fr) | 2021-04-28 |
RU2019107379A3 (es) | 2020-11-23 |
WO2018036819A1 (en) | 2018-03-01 |
KR20190039933A (ko) | 2019-04-16 |
MX2019001854A (es) | 2019-11-11 |
BR112019003673A2 (pt) | 2019-05-21 |
US10543256B2 (en) | 2020-01-28 |
US20180055914A1 (en) | 2018-03-01 |
CA3029456A1 (en) | 2018-03-01 |
TW201811311A (zh) | 2018-04-01 |
KR102395835B1 (ko) | 2022-05-10 |
EP3503905A1 (en) | 2019-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019003173A2 (pt) | formulação farmacêutica, uso de uma formulação farmacêutica e método para evitar o aumento da viscosidade durante o armazenamento de uma formulação farmacêutica | |
AR113422A2 (es) | Agentes tensioactivos reconstituidos que tienen propiedades mejoradas | |
UY36542A (es) | Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa | |
CO6470858A2 (es) | Composición tensioactiva reconstituida mejorada que contiene análogos de la proteína tensioactiva b (sp-b) y de la proteína tensioactiva c (sp-c) | |
AR127361A2 (es) | Composición farmacéutica de partículas de lipoplejos y arn, composición acuosa y método de preparación | |
BR112018005316A2 (pt) | ?uso de lisina para restabelecer/aumentar a atividade antibacteriana na presença de surfactante pulmonar de antibióticos inibidos desse modo? | |
MY195190A (en) | Controlled-Release Cnp Agonists With Increased Nep Stability | |
AR088382A1 (es) | Formulaciones de etanercept estabilizadas con xilitol | |
BR112014004460A2 (pt) | material polimérico para um recipiente isolado | |
AR094583A1 (es) | Composiciones que incluyen agentes para conferir carácter hidrofóbico y estabilizante y métodos para elaborar y usar los mismos | |
PE20230735A1 (es) | Metodos de tratamiento de trastornos del desarrollo con gaboxadol | |
CL2019001366A1 (es) | Formulaciones tamponadas exendina (9-39). | |
RS53598B1 (en) | TOPICAL PREPARATIONS FOR THE CONSERVATION OR RE-ESTABLISHMENT OF MALFIN INTEGRITY | |
PH12016502100A1 (en) | Liquid formulation comprising gm-csf neutralizing compound | |
PE20171334A1 (es) | Formulacion en polvo nasal para el tratamiento de hipoglicemia | |
AR093569A1 (es) | Tensioactivos pulmonares reconstituidos | |
BR112019008858A2 (pt) | produto da indústria do tabaco e método para fabricar um produto | |
BR112016021777A2 (pt) | Formulações de fator ix liofilizado | |
AR109386A1 (es) | Formulación farmacéutica estable que comprende una composición de un agente tensioactivo pulmonar reconstituido | |
ECSP20055797A (es) | Métodos y composiciones para tratar enfermedades pulmonares crónicas | |
CL2018001151A1 (es) | Suspensión acuosa para administración oral y método para su preparación | |
BR112015022484A2 (pt) | formulações com oxidação reduzida | |
BR112021019612A2 (pt) | Formulações, recipiente, artigo de fabricação, método para produzir a formulação e método para inibir a agregação de uma proteína presente em uma solução aquosa | |
MX2021014310A (es) | Formulaciones de terlipressina. | |
MY198474A (en) | Formulations of polyalkylene oxide-asparaginase and methods of making and using the same |